What is Cytotec approved for?
What is Cytotec approved for?
Cytotec (misoprostol) is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)-induced gastric ulcers in patients at high risk of complications from gastric ulcer, eg, the elderly and patients with concomitant debilitating disease, as well as patients at high risk of …
When was misoprostol approved?
The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone. Misoprostol was granted FDA approval on 27 December 1988.
What is the difference between Cytotec and Pitocin?
Cytotec, also known as Misoprostol, is a drug administered in pill form that is used to treat gastric ulcers. Pitocin is another popular labor-inducing drug (administered intravenously) that is made from a synthetic version of a naturally occurring hormone (oxytocin) used to stimulate contractions in pregnant women.
Is Cytotec FDA approved?
Misoprostol (Cytotec) is safe and effective for induction of labor, although it is not approved by the Food and Drug Administration (FDA) for use in pregnancy.
What is the drug release rate for Misodel?
MISODEL vaginal insert is a controlled release formulation that swells in the presence of moisture, causing drug release to occur. Misoprostol is released in vivo at a mean rate of approximately 7 micrograms/hour over a period of 24 hours. Drug release continues as long as MISODEL is in the vagina.
What is the chemical name for modified release misoprostol?
MISODEL® Modified-Release Pessary (vaginal insert) misoprostol 200 micrograms The chemical name for misoprostol (also known as prostaglandin E1 or PGE1) is (±)-(11a, 13E)-11, 16-dihydroxy-16-methyl-9-oxo-prost-13-en-1-oic acid-methyl ester. The structural formula (relative stereochemistry) is:
When will ferferring misodeltm be available in Europe?
Ferring plans to launch the product in the various European countries beginning in 2014. MISODELTM (MYSODELLETM in some European countries) has been approved for induction of labour in women with an unfavourable cervix, from 36 weeks of gestation, in whom induction is clinically indicated.
What is the difference between misodeltm and DVI?
The study compared the 200 mcg MISODELTM controlled release vaginal delivery system with the 10-mg dinoprostone vaginal insert (DVI), in terms of efficacy and safety. The EXPEDITE study showed that MISODELTM significantly reduced the time to vaginal delivery compared to DVI.
